Better Health for All

Kestra Medical Technologies' core product, the ASSURE Wearable Cardioverter Defibrillator (WCD) System, is designed to deliver therapy for life-threatening ventricular arrhythmias and protect patients from sudden cardiac arrest, a leading cause of death.

The company's primary focus is on this life-saving technology, indicating that 100% of its portfolio delivers revolutionary health benefits. Clinical studies show high patient compliance with a median daily wear time of 23.3 hours and detection of ventricular arrhythmias in 4% of patients, leading to timely escalation of care. No serious adverse events or unanticipated adverse device effects were reported in clinical studies, with reported adverse events primarily being mild skin irritation and musculoskeletal issues. One malfunction event was reported where a service error code was received, but no patient injury or adverse event occurred. The instructions for use document details potential complications, including failure to sense arrhythmias, inappropriate shocks, and device malfunction. The company's product focuses on treatment rather than prevention. Clinical studies followed ethical guidelines, including informed consent and independent review of adverse events.

Fair Money & Economic Opportunity

Kestra Medical Technologies, Ltd. (KMTS.US) is a medical technology company focused on developing and commercializing solutions for cardiac rhythm management, specifically implantable cardioverter-defibrillator (ICD) systems.

The company's core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to 'Fair Money & Economic Opportunity,' which assess financial institutions' practices regarding financial services, are not applicable to KMTS.US.

Fair Pay & Worker Respect

Kestra Medical Technologies has an overall employee recommendation rate of 88% of employees who would recommend working at the company to a friend.

There is no public record of substantiated labor-law or human-rights violations in the past three years, nor any mention of regulatory actions, fines, or compliance issues across the provided articles.

Fair Trade & Ethical Sourcing

No quantitative data regarding Kestra Medical's fair trade and ethical sourcing practices, including certifications, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage, materials risk, or supplier diversity spend, is available in the provided article.

The article explicitly states that significant data gaps exist for these metrics.

Honest & Fair Business

Kestra Medical Technologies has a formal whistleblower policy, including an anonymous 24/7 hotline (1-833-980-2017) administered by an outside vendor with voice masking.

The policy prohibits retaliation for good faith reports and protects disclosures to governmental agencies. This policy applies to all Kestra affiliates and subsidiaries worldwide. However, there is no information on the frequency of training or the program's effectiveness. The company identified material weaknesses in its internal control over financial reporting as of October 31, 2025. A Code of Conduct, effective March 5, 2025, applies to all affiliates and subsidiaries worldwide, promoting honest and ethical conduct and fair dealing. It also mentions an FCPA Anti-Corruption Compliance Policy and a toll-free Compliance Hotline. However, the policy's training frequency and effectiveness metrics are not specified. The company relies on independent third-party surveys and market research data, and its financial statements are audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm. However, there is no explicit mention of the percentage of ethical claims independently verified.

Kind to Animals

Kestra Medical Technologies conducted nine pre-clinical animal studies to test the safety and effectiveness of its ASSURE WCD shock waveform, using a total of 151 swine.

For example, one effectiveness study involved 36 swine, and another safety study used 14 swine. Animal care during these studies complied with the Guide for Animal Care and Use of Laboratory Animals (NIH), Public Health Service (PHS) Policy, USDA Animal Welfare Act and Regulations, and IACUC Standard Operating Procedures.

Safe & Smart Tech

Kestra Medical Technologies holds ISO 13485 certification for its Medical Device Quality Management System.

The company has a vulnerability disclosure process, committing to an initial response within 5 business days. Cybersecurity considerations are integrated into product development, aligning with the ISO 13485 system. The company's privacy policy states compliance with HIPAA for Protected Health Information and local laws, and it supports Do Not Track requests. California residents are afforded rights to access, delete, and correct their personal information, with methods provided for submitting requests. Data is retained only as long as necessary for business needs or legal requirements, and the company does not knowingly collect data from children under 18. There are no documented incidents of unauthorized data use.